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Introduction: In the field of skin tissue engineering, gelatin-chondroitin-6-sulfate-hyaluronic acid (Gel-C6S-HA)
stents are a suitable bio skin substitute. The purpose was to investigate the effect of genetically-modified hair follicle
stem cells (HFSCs), combined with Gel-C6S-HA scaffolds, on the vascularization of tissue-engineered skin.
Methods: Three-dimensional (3D) Gel-C6S-HA scaffolds were prepared by freeze-drying. Vascular endothelial growth
factor (VEGF) 165 gene-modified rat HFSCs (rHFSCs) were inoculated into the scaffolds and cultured for 7 days. Two
bilateral full-thickness skin defects were created on the back of 18 Sprague–Dawley rats. Rats were randomly divided
into four groups: Group A, HFSCs transduced with VEGF165 seeded onto Gel-C6S-HA scaffolds; Group B, HFSCs
transduced with empty vector seeded onto Gel-C6S-HA scaffolds; Group C, Gel-C6S-HA scaffold only; Group D,
Vaseline gauze dressing. These compositions were implanted onto the defects and harvested at 7, 14 and 21 days.
Wound healing was assessed and compared among groups according to hematoxylin-eosin staining, CD31 expression,
alpha smooth muscle actin (α-SMA) and major histocompatibility complex class I (MHC-I) immunohistochemistry, and
microvessel density (MVD) count, to evaluate the new blood vessels.
Results: SEM revealed the Gel-C6S-HA scaffold was spongy and 3D, with an average pore diameter of 133.23 ± 43.36 μm.
Cells seeded on scaffolds showed good adherent growth after 7 days culture. No significant difference in rHFSC
morphology, adherence and proliferative capacity was found before and after transfection (P >0.05). After 14 and
21 days, the highest rate of wound healing was observed in Group A (P <0.05). Histological and immunological
examination showed that after 21 days, MVD also reached a maximum in Group A (P <0.05). Therefore, the number
of new blood vessels formed within the skin substitutes was greatest in Group A, followed by Group B. In Group C,
only trace amounts of mature subcutaneous blood vessels were observed, and few subcutaneous tissue cells
migrated into the scaffolds.
Conclusions: Tissue-engineered skin constructs, using 3D Gel-C6S-HA scaffolds seeded with VEGF165-modified rHFSCs,
resulted in promotion of angiogenesis during wound healing and facilitation of vascularization in skin substitutes. This
may be a novel approach for tissue-engineered skin substitutes.* Correspondence: quanrenfu8@163.com
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Large skin defects caused by trauma often result in severe
physical disability and even death. Current treatment
methods include wound dressings, autologous skin grafts,
allogeneic skin grafts and tissue-engineered skin repair, to
name a few. However, limitations exist for these ap-
proaches. For example, wound dressings have no physio-
logical function, autologous skin grafts have limited area
coverage and allogeneic skin grafts often lead to an im-
munological rejection response, probably skin shedding
and necrosis, which could lead to secondary damage in
the patient and increased morbidity. Application of tissue-
engineered skin could potentially resolve many of these
limitations. Current tissue-engineered skin repair ap-
proaches are often complicated by wound infection, non-
union and other complications, and treatment efficacy is
unsatisfactory. This is closely related to the extent of
vascularization of the repaired wound [1-3]. Poor angio-
genesis capability can lead to a limited vascular system
and insufficient supply of nutrients to the early grafted
skin, which in turn can lead to necrosis of the skin substi-
tute and graft failure. Facilitation of the process of
vascularization is thus an unmet clinical need in the field
of skin tissue engineering [4-6]. Composite delivery sys-
tem construction [7,8], screening of cell-seed types [9-12],
incorporation of effective active factors [13,14] and apply-
ing genetically-modified cells [10-12] can promote early
vascularization of tissue-engineered skin. Gelatin–chon-
droitin-6-sulfate–hyaluronic acid (Gel-C6S-HA) scaffolds
are known to be hydrophilic with good tissue compatibil-
ity and biodegradability [15,16]. Gelatin, a denatured colla-
gen, is nontoxic, is biocompatible and can provide a
microenvironment for adherence, growth, proliferation
and differentiation of cells. Incorporation of chondroitin-
6-sulfate into gelatin scaffolds resulted in a scaffold with
higher resistance to collagenase degradation, higher elastic
modulus and a more porous structure than gelatin scaf-
folds [17,18]. It can significantly enhance the flexibility
and porous structure of the scaffold. As the strongest
natural moisturizing factor and when used at a certain
concentration, hyaluronic acid can effectively improve
scaffold strength and the in vivo degradation rate, pre-
vent drying of the scaffold and provide nutrients to the
cells within the scaffold [18,19]. In the tissues of the
skin, this characteristic is of fundamental importance
for water retention. Hyaluronic acid can be further
modified by hydroxyl and carboxyl functional groups
with specific cell or extracellular matrix components,
to enhance its biological function [20].
Hair follicle stem cells (HFSCs) are undifferentiated
cells with fast self-renewing potential and rapid in vitro
proliferative capacity, localized mainly in the bulge of
the hair follicle outer root sheath [21,22]. Studies have
shown that cultured HFSCs have high colony-formingability and very high regenerative potential [23]. HFSCs
not only can differentiate into hair follicle cells, but also
into nerve cells, melanoma cells, smooth muscle cells
and epithelial cells, to name a few. HFSCs can be har-
vested from follicle skin and hair, and their numbers are
extremely impressive. HFSC harvesting poses no serious
complications and provides the most readily available
source of stem cells [24-27].
As a specific vascular endothelial cell mitogen, vascular
endothelial growth factor (VEGF) plays an important role
in angiogenesis and the repair process after tissue ische-
mia. There are five subtypes of VEGF, with VEGF165 be-
ing the most active, widely distributed and main active
form in the body [28,29]. However, VEGF165 has a very
short half-life and can be easily diluted after injection into
the body. Shima and colleagues reported that the bio-
logical half-life of VEGF165 is 30 to 45 minutes under
normal oxygen partial pressure, and 6 to 8 hours under
hypoxia [30]. Adding exogenous VEGF165 into tissue-
engineered skin therefore has limited therapeutic efficacy.
To overcome the limitations of pure protein treatment,
application of gene therapy should be considered.
The purpose of this study was to analyze the effects of
genetically-modified HFSCs combined with Gel-C6S-HA
scaffolds on the vascularization of skin substitutes. First,
HFSCs with high proliferative capacity were obtained
using double digestion with dispase and type IV collage-
nase. Cells were then screened by microisolation and dif-
ferential adherence of type IV collagen. HFSCs were then
genetically modified using lentivirus-mediated VEGF165,
after which sustained and stable expression of VEGF165
at high abundance was examined. Rat hair follicle stem
cells (rHFSCs) were then inoculated into Gel-C6S-HA
scaffolds and cultured for 7 days. rHFSC morphology, ad-
herence and proliferation were observed. Finally, the con-
structed tissue-engineered skin was grafted onto the back
of rats with full-thickness skin defects to evaluate angio-
genesis potential, wound healing and immunogenicity of
the composite scaffolds at different time points.
Methods
Preparation of Gel-C6S-HA scaffolds
Gelatin (5% (w/v); Sigma, San Jose, CA, USA) was dis-
solved in 10 ml distilled water and slowly added to
chondroitin-6-sulfate (0.05% (w/v); Sigma) and hyalur-
onic acid (0.1% (w/v); Sigma) to form a suspension solu-
tion. The solution was stirred for 60 minutes at room
temperature with a magnetic stirrer, and then cross-
linker solution (0.5% (w/v) 1-ethyl-3-(3-dimethylamino-
propyl) carbodiimide and 0.25% (w/v) N-hydroxysucci-
nimide; Sigma) was added dropwise to the suspension
solution and stirred for 15 minutes. The mixture was
injected into wells of a cell culture plate (2 cm diameter,
1.8 cm height; Corning-costar, NY, USA). Plates were
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structs were then frozen at −80°C for 2 hours and lyophi-
lized with a freeze dryer (CHRIST, Vaihingen, Germany)
for 48 hours. Gel-C6S-HA porous sponge-like scaffolds,
with a thickness of 2 mm, were obtained. Scaffolds were
soaked in 75% (v/v) ethanol followed by phosphate-
buffered saline (PBS), each for 48 hours, and were dried
with sterile gauze for further use. The macroscopic appear-
ance of the Gel-C6S-HA scaffold was photographed using
a digital camera (Sony, Tokyo, Japan).Isolation and culture of rat HFSCs
Sprague–Dawley rats were provided by the Experimental
Animal Center of Zhejiang Chinese Medical University
(batch number: SCXK (Zhejiang) 2013‒0023). The ex-
perimental protocol was approved by the Experimental
Animal Ethics Committee of Zhejiang Chinese Medical
University, and animal disposal was in line with animal
ethics requirements. Two Sprague–Dawley rats (1 week
old) were euthanized by cervical dislocation. The skin
near the beards was cut with ophthalmic scissors, rinsed
(3×) in PBS and digested with a mixture of 1% (w/v) dis-
pase (Gibco, GrandIsland, NY, USA) and 1% (w/v) type
IV collagenase (Gibco) at 37°C for 90 minutes, prior to
further PBS rinsing (3×). Hair follicles were isolated
from the connective tissue sheath using stereomicro-
scopy and a needle. The two ends were cut and the
bulge was inoculated in a plastic dish pre-coated with
Matrix gel (Gibco), prior to adding 1 ml medium. The
medium components comprised: 86.896% (v/v) Dulbec-
co’s modified Eagle’s medium/F12 medium (Gibco), 10%
(v/v) Knockout™ Serum Replacement (Gibco), 1% (v/v)
penicillin–streptomycin mixture (Solarbio, Beijing, China),
1% (v/v) L-glutamine (Gibco), 1% (v/v) nonessential amino
acids (Gibco), 0.002% (v/v) epidermal growth factor
(Becton, Dickinson and Company, Franklin Lakes, NJ,
USA), 0.001% (v/v) basic fibroblast growth factor (Becton,
Dickinson and Company), 0.1% (v/v) hydroxyl ethanol
(Gibco) and 0.001% (v/v) hydrocortisone (Sangon Biotech,
Shanghai, China). HFSCs were cultured at 37°C, 5% (v/v)
carbon dioxide for 2 days. Medium (5 ml) was added
following tissue adherence and changed every 3 days
thereafter. Cell migration and growth conditions were
then observed.
The Petri dish was coated with type IV collagen (Sigma,
AL, St. Louis, MO, USA) and left for 1 hour at room
temperature. The primary cells were digested with
TrypLE™ Express trypsin substitute enzyme (Gibco) and
inoculated in culture dishes. Nonadherent cells and
medium were aspirated after 20 minutes and adherent
cells were further cultured in the medium. Passage (P) 2
generation cells were further purified as well as the pri-
mary rHFSCs.Characterization of relevant genes by quantitative
polymerase chain reaction
Quantitative polymerase chain reaction (PCR) was car-
ried out on purified rHFSCs (P3) as follows. Six target
genes (cytokeratin (CK) 10, CK15, CD34, CK19, integrin
β1, integrin α6) and one internal reference gene (beta-
actin (ACTB)) were amplified in a reaction tube. Primers
were designed using Premier 5.0 software (Primer,
Toronto, Canada) and the primer information is pre-
sented in Table 1. The PCR reaction included 10 μl of
2× SYBR Green Mix, 1 μl Primer Mix, 1 μl template and
8 μl ultrapure water. The reaction mixture was dis-
pensed in a PCR eight-tube and mixed well. Quantitative
PCR was carried out using a fluorescent quantitative
PCR instrument (Bio-Rad, Hercules, CA, USA) with the
SYBR Green method. The relative expression of mRNA
for each gene was measured using the ΔCt method:
ΔCt ¼ target gene cycle threshold value
− reference gene cycle threshold value
Characterization of cells using immunofluorescence
staining
rHFSCs (P3) were inoculated on a slide and cultured for
2 days. Cells were rinsed with PBS–Tween, fixed with
4% (w/v) paraformaldehyde (Kelong Chemical Reagent
Company, Chengdu, China) and blocked with 5% (w/v)
bovine serum albumin at room temperature. Integrin β1
(1:100; Abcam, Cambridge, UK), integrin α6 (1:50;
Abcam) and CK15 (1:100; Abcam) antibodies were then
added separately. PBS–Tween was added instead of pri-
mary antibody in the control group. After incubation at
room temperature and washing with PBS–Tween,
fluorescein-labeled secondary antibody was added (1:100;
Jackson, San Francisco, CA, USA) and incubated in the
dark for 30 minutes. 4′,6-Diamidino-2-phenylindole
(1:2,000 dilution; Roche, La Roche, Switzerland) was
then added and incubated for 5 minutes for nuclear
staining. Cells were then air dried in the dark, mounted
with Mounting Solution and observed using fluorescence
microscopy (Olympus, Tokyo, Japan).
Cell proliferation measurement
rHFSCs (P3, P5, P7 and P9) with good growth status were
inoculated in a dish at a concentration of 1 × 105 cells/well.
Cells were counted at days 1, 2, 3, 4, 5, 6 and 7 with a
hemocytometer. The growth curve was plotted from an
average of six replicates.
Modification of rHFSCs with lentiviral gene
Package of lentivirus
A calcium phosphate transfection kit (Biowit Technologies,
Shengzhen, China) was used to package the lentivirus.
Cells (293 T) were inoculated 24 hours in advance and
Table 1 Primer sequences used for reverse transcription–polymerase chain reaction gene expression analysis
Gene 5′ to 3′ Primers Production size (base pairs)
CK10 Forward TTGGAAACCTGCAAATAACCC 175
Reverse ATCATAGACGAAAGGACTCTACCC
CK15 Forward AAAACCGTCGGGATGTAGAGG 94
Reverse TTGCTGGTCTGGATCATTTCTGT
CK19 Forward CCAAGTTTGAGACAGAACAGGC 156
Reverse CGTGGTTCTTCTTCAGGTAGGC
CD34 Forward CCTGCCGTCTGTCAATGTTTC 146
Reverse GCACTCCTCGGATTCCTGAAC
Integrin β1 Forward ATCATGCAGGTTGCAGTTTG 72
Reverse CGTGGAAAACACCAGCAGT
Integrin α6 Forward CGTGGTTCTTCTTCAGGTAGGC 188
Reverse CACATCTATGGACGCCCTCAC
ACTB Forward GCTATGTTGCCCTAGACTTCGA 173
Reverse GATGCCACAGGATTCCATACC
VEGF165 Forward CACCCACCCACATACATACA 169
Reverse CTCCCAACTCAAGTCCACA
β-actin Forward GTCCCTCACCCTCCCAAAAG 20
Reverse GCTGCCTCAACACCTCAACCC 21
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medium was replaced with high-glucose Dulbecco’s modi-
fied Eagle’s medium (Gibco) +10% (v/v) fetal bovine
serum (Gibco) without antibiotics. The target plasmid
(pLV-VEGF165–internal ribosome entry site–enhanced
green fluorescent protein) and packaging plasmids
(vesicularstomatitisvirusG (VSVG), Respiratory Syncytial
Virus - Respiratory Entericorphan Virus (RSV-REV) and
Rev response element (RRE)) were added to Hank’s bal-
anced salt solution (Gibco) at a ratio of 2:1:1:1 (w/w).
Components were mixed well and supplemented with
double-distilled water. The mixture was referred to as So-
lution A. After addition of CaCl2, the solution was left to
sit at room temperature for 20 minutes, prior to adding
dropwise to a cell culture dish. After 10 to 12 hours,
medium comprising high-glucose Dulbecco’s modified
Eagle’s medium +10% (v/v) fetal bovine serum +1%
(v/v) penicillin–streptomycin was added. After
48 hours, while strong green fluorescence was
expressed, the supernatant was collected and stored
at −80°C for further use. Packaging of pLV–internal
ribosome entry site–enhanced green fluorescent protein
plasmid was carried out using identical steps.
Transfection of rHFSCs with lentivirus
rHFSCs were cultured with 50 μl virus in an incubator
at 37°C with 5% (v/v) carbon dioxide for 30 minutes. Add-
itional medium was then added and the cells were further
cultured. Expression of green fluorescence was observedusing a fluorescence microscope (Olympus) after 72 hours.
Fields of view (12 × 200) were randomly observed to cal-
culate the transfection efficiency:
Transfection efficiency
¼ positive cells=total number of cells in the visual field
 100%
The average was calculated from three replicates. Cells
were observed again at day 14.
Reverse transcription-polymerase chain reaction
Total RNA was extracted using Trizol RNA extraction
kit (Kang Century, Shanghai, China), according to the
manufacturer’s instructions. cDNA was obtained by add-
ing reverse transcriptase according to the manufacturer’s
instructions. Primers were designed using Premier5.0 soft-
ware, and the primer information is presented in Table 1.
The PCR reaction mixture included 1 μl template, 2 μl of
10 × PCR buffer, 1 U Taq DNA polymerase, 0.5 μl each 5′
and 3′ primer, and the volume was brought up to 20 μl
with ultrapure water. The product was run on a 2% (w/v)
agarose gel for 30 minutes. Imaging was obtained and de-
veloped using an imaging system (Bio-Rad, San Francisco,
CA, USA).
Western blot
Cells were rinsed with cold PBS (3×) and proteins were
extracted on ice. Proteins were run on a sodium dodecyl
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to a polyvinylidene fluoride membrane. The membrane
was soaked with 5% (w/v) skimmed milk for 1 hour, and
then blocked in blocking solution overnight at room
temperature. After rinsing the membrane in PBS (3×),
VEGF165 antibody (1:2,000; R&D Systems, Minneapolis,
MN, USA) was added and incubated for 1 hour. After
rinsing with Tris-buffered saline–Tween (3×), goat anti-
rabbit secondary antibody (1:1,000; Jackson, West Grove,
PA, USA) was added and incubated at room temperature
for 1 hour. After washing the membrane with Tris-
buffered saline–Tween (3×), electrochemiluminescence
(ECL) reagent was added, color was developed using an
odyssey machine (LI-COR, Lincoln, NE, USA) and images
were obtained.
Cell morphology, adherence and proliferation on scaffolds
rHFSCs were digested into single-cell suspensions prior
to inoculation in Gel-C6S-HA scaffolds (Groups A, B
and C) at a density of 5 × 106/cm2 and were gas–liquid
incubated at 37°C with 5% (v/v) carbon dioxide. After 1
and 7 days, cell-seeded scaffolds were fixed in 2.5% (v/v)
glutaraldehyde solution overnight, prior to fixing with
1% (v/v) osmium tetroxide for 1 hour. After a PBS rinse
(3×), constructs were dehydrated with gradient acetone
50 to 100% (v/v). Following critical point drying (Leica,
Osaka, Japan), samples were sputter-coated with gold and
observed using scanning electron microscopy (Hitachi,
Tokyo, Japan) at a voltage of 15 kV.
Proliferation was measured using the CCK-8 Kit (Qcbio
Science & Technologies, Shanghai, China). rHFSCs were
inoculated on the three-dimensional scaffolds. At 1, 3, 5
and 7 days, 10% (v/v) CCK-8 was added to the medium
and incubated for 4 hours. Optical density at 450 nm was
measured using a microplate reader (BioTek, Winooski,
VT, USA).
Grafting of composite scaffolds
Rats were injected intraperitoneally with 1% (w/v) sodium
pentobarbital (40 mg/kg), preoperatively, with fixed limbs.
Rat backs were disinfected with povidone–iodine and the
operative areas were treated for hair removal. Skin was in-
cised along marked lines, deep to the subcutaneous super-
ficial fascia layer, and the full-thickness skin was removed.
Four 1.2 cm × 1.2 cm wounds were opened 1 cm from the
dorsal midline, two on each side, spaced by 1 cm. The rats
were randomly divided into three batches and four groups:
Group A (experimental group), HFSCs/Gel-C6S-HA scaf-
fold transfected with VEGF165; Group B, HFSCs/Gel-
C6S-HA scaffold transfected with empty vector; Group C,
Gel-C6S-HA scaffold; and Group D, Vaseline gauze
(Zhengde Surgical Dressing Company, Shaoxing, China).
Materials for all four groups were grafted into the wounds,
which were then interrupted sutured with 5–0 silk threadat the wound edge, covered with sterile dressing, and fixed
by strapping. To prevent the rat biting the wound area, a
resilient protection coat was designed and applied.
For postoperative treatment, each rat was housed in a
separate cage. The outer layer of the surgical dressings
was soaked and replaced immediately with sterile gauze.
Sodium penicillin (1,000,000 U/kg; North China Pharma-
ceutical Company, Shanghai, China) was injected daily.
Observation of postoperative wound
At 7, 14 and 21 days after grafting, wounds were photo-
graphed using a digital camera (Sony, Tokyo, Japan) and
the rate of wound healing was calculated using Image-Pro
Plus 6.0 image analysis software (Media Cybernetics,
Rockville, MD, USA):
Wound healing rate %ð Þ
¼ ðtotal wound area − the wound area at time of observationÞ
=total wound area  100%
When the majority of the graft was absorbed and
tightly combined with the surrounding wound, this was
considered as healed.
Tissue sections
Fresh samples were rinsed with saline, fixed with 4%
(w/v) paraformaldehyde solution, embedded in paraffin
and sliced (6 μm). Slices were dehydrated with gradient
ethanol, stained with hematoxylin and eosin, treated
with xylene and mounted with neutral balsam. Each
inverted slice was observed using phase contrast mi-
croscopy (Olympus).
Immunological examination
Fixation, embedment and slicing were carried out as de-
scribed above. After dewaxing, hot antigen retrieval was
performed in 0.01 M citrate buffer solution for 15 minutes.
Samples were blocked with 8% (w/v) bovine serum al-
bumin, then incubated with anti-CD31 (1:100; Abcam)
and anti-alpha smooth muscle actin (anti-α-SMA, 1:150;
Abcam) antibodies overnight at 4°C, separately. After
washing with PBS (3×), horseradish-peroxidase-labeled
secondary antibody (1:200; Jackson) was added and incu-
bated at room temperature for 2 hours followed by PBS
washing (3×). 3,3′-Diaminobenzidine solution was then
added to each sample and incubated for 20 minutes to
develop the color. After mounting, inverted slices were
observed using phase contrast microscopy.
Microvessel density measurement
Immunohistochemical staining for CD31 was carried out
on Groups A to C postoperatively at 7, 14 and 21 days.
Brown dots present in images of endothelial cells indi-
cated positive staining. Six random, unrepeated fields
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newly grown microvessels (brown staining) was calcu-
lated using Image-Pro Plus 6.0, according to the conver-
sion of each vision field area of 0.1885 mm2 being equal
to 1 mm2. An average of six replicates was recorded as
the microvessel density (MVD).
Immunogenicity examination
Fixation, embedment, slicing, dewaxing and antigen re-
trieval methods were carried out as described above.
Briefly, samples were blocked with 8% (w/v) bovine serum
albumin overnight at 4°C. Histocompatibility antibody
major histocompatibility complex class I (MHC-I, 1:20;
Abcam) was added and incubated at 4°C overnight.
After washing with PBS (3×), fluorescein-labeled second-
ary antibody (1:50; Jackson) was added and incubated at
room temperature for 1 hour. After washing with PBS
(3×), 4′,6-diamidino-2-phenylindole was added for nuclei
staining. Samples were observed using fluorescence mi-
croscopy (Olympus) after mounting.
Statistical analysis
Differences between groups were analyzed using the SPSS
version 18.0 least significant difference test (SPSS Inc.
Chicago, IL, USA). P <0.05 indicates a statistically sig-
nificant difference.Figure 1 Observation of Gel-C6S-HA scaffold characteristics. (a), (b) Th
connective transport holes between pores, observed using scanning elec
(c) Pore sizes were not uniform, with an average pore diameter of 133.23 ± 43
hyaluronic acid (Gel-C6S-HA) scaffold.Results
Morphology of three-dimensional Gel-C6S-HA scaffolds
Gel-C6S-HA scaffolds made from freeze-drying were
observed using scanning electron microscopy (Figure 1).
By applying different magnifications, scaffolds were ob-
served to form a spongy three-dimensional structure
with transport holes between pores, which were circular
or polygonal (Figure 1a,b). Using Image-Pro Plus 6.0
software, the average pore diameter was calculated to be
133.23 ± 43.36 μm, with varying sizes (Figure 1c). The
macroscopic appearance of the Gel-C6S-HA scaffold is
showed in Figure 1d.
Primary culture of rat HFSCs and their biological
characteristics
By 3 days, a small number of cells had migrated from
the periphery of the follicle bulge (Figure 2a). By 7 days,
the number of cells had gradually increased (Figure 2b).
On 14 days, excess tissue was removed and adherent
cells were observed to be tightly packed on the vessel
wall, typical of epithelial cells (Figure 2c,d). After type IV
collagen sorting of adherent cells (twice), cells showed
typical cobblestone-like and nest-like morphology, with
a clear three-dimensional appearance and high refractive
index. Furthermore, cells aggregated and formed colonies,
had a central cytoplasm and had round nuclei, the latter
of which were large and prominent (Figure 2e,f).e scaffold formed a three-dimensional sponge-like structure, with
tron microscopy. Pores were circular or polygonal in microstructure.
.36 μm. (d) Macroscopic appearance of the gelatin–chondroitin-6-sulfate–
Figure 2 (See legend on next page.)
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Figure 2 Isolation and biological characteristics of rat hair follicle stem cells. Primary cell culture on (a) day 3, (b) day 7 and (c), (d) day 14.
Rat hair follicle stem cells (HFSCs; P2) (e) before and (f) after purification. (g) Quantitative polymerase chain reaction results of six correlated
genes in rat HFSCs; ACTB was used as the reference gene. (h) Immunofluorescence staining for expression of cytokeratin (CK) 15, integrin α6 and
integrin β1. (i) Growth curves of different generations of HFSCs. Scale bars: 100 μm (a to c, e, f, h); 250 μm (d). Ct, cycle threshold; P, passage.
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CK15, CK19, CD34, integrin α6 and integrin β1 genes.
Expression levels of CK19, integrin α6 and integrin β1
genes were high, with moderate CK15 expression and
low expression for CD34 and CK10 (Figure 2g). Immuno-
logical staining identified positive expression for CK15
(red florescence in cytoplasm), integrin α6 and integrin β1
in HFSCs. Conversely, expression of these markers was
negative in the control group, which was counterstained
with 4′,6-diamidino-2-phenylindole (Figure 2h).
Cell growth curves were used to determine the prolifer-
ative capacity of the HFSCs (Figure 2i). At P3, P5, P7 and
P9, HFSCs were in the interphase period within 2 days
after inoculation and grew slowly. By 3 days, stem cell
clones formed. From 5 to 6 days, cells were in the loga-
rithmic growth phase with relatively rapid cell prolifera-
tion, after which the cell growth rate began to slow down,
entering into a plateau period. From the seventh gener-
ation (P7 cells), cell proliferation gradually decreased.Genetic modification of rat HFSCs by VEGF165
Strong green fluorescence was visible 72 hours after
transfection with lentivirus (Figure 3a,b). The transfection
efficiency was 71.52 ± 1.83%. Cells were continuously ob-
served for 14 days, and the lentiviral transfection efficiency
was steady at 85.76 ± 1.91%.Figure 3 VEGF165 gene-modified rat hair follicle stem cells. (a) Fluore
staining indicates that the target plasmid pLV–VEGF165–IRES–EGFP was suc
contrast image. (c) Reverse transcription-polymerase chain reaction for VEG
VEGF165 protein. Scale bars: 100 μm (a, b). EGFP, enhanced green fluoresc
growth factor.Reverse transcription-PCR (Figure 3c) showed the
VEGF165 mRNA expression level was significantly higher
in the VEGF165 transfection group compared with the
empty vector transfection group. Western blot results
(Figure 3d) showed that VEGF165 protein was highly
expressed in the VEGF165 transfection group, but not
in the empty vector transfection group.Rat HFSC morphology, adherence and proliferation ability
on scaffolds
By 1 day, few adherent cells were observed in Groups A
to C and the cells were spherical (Figure 4a,b,c). By
7 days, scanning electron microscopy was used to ob-
serve cell spreading and firm adherence to the scaffold
walls (Figure 4d,e,f). CCK-8 showed there was no signifi-
cant difference in the proliferative capacity of cells within
the three groups (Figure 4g; P >0.05), indicating the scaf-
fold had very good biocompatibility and was nontoxic.
Taken together, gene-modified rHFSCs could adhere and
grow well in the wall of the scaffolds.Transplantation of cell-seeded scaffolds
After anesthesia, hair removal was carried out in the
surgery zone on the back of the mice, as shown in Figure 5a.
The four skin substitute groups were transplanted
(Figure 5b,c) after sufficient hemostasis. By applyingscein isothiocyanate image using fluorescence microscopy. Green
cessfully transfected into the hair follicle stem cells (HFSCs). (b) Phase
F165 expression after transfection. (d) Western blot for expression of
ent protein; IRES, internal ribosome entry site; VEGF, vascular endothelial
Figure 4 Hair follicle stem cell morphology, adherence and proliferation on scaffolds. (a), (b), (c) After 1 day of culture, no significant
difference was observed between all groups with respect to cell morphology, with few adherent cells, the majority being spherical. (d), (e), (f)
After 7 days of culture, all cells were firmly adhered to the scaffold and were growing three-dimensionally along the scaffold. (g) After transfection
of VEGF165, hair follicle stem cells (HFSCs) adhered efficiently to the scaffold wall. There was no significant difference in proliferative capacity with
the control group. (a), (d) HFSCs after VEGF165 transfection (Group A). (b), (e) Control group with empty support (Group B). (c), (f) Control group
(Group C). HFSCs/pLV-VEGF165-IRES-EGFP, HFSCs transduced with VEGF165 seeded on Gel-C6S-HA scaffolds; HFSCs/pLV-IRES-EGFP, HFSCs
transduced with empty vector seeded on Gel-C6S-HA scaffolds: HFSCs, HFSCs seeded on Gel-C6S-HA scaffolds. EGFP, enhanced green fluorescent
protein; Gel-C6S-HA, gelatin–chondroitin-6-sulfate–hyaluronic acid; IRES, internal ribosome entry site; OD, optical density; VEGF, vascular endothelial
growth factor.
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ively protected from rat biting to reduce infection and
destruction.
Observation of postoperative skin wounds
After 7 days, there was no significant swelling, exudate
or infection observed for all groups. In all cases, the trans-
plant was in close contact with the wound. For Group D,
the wound was dry and had red granulation (Figure 6a,b,c).
After 14 and 21 days, the wound area of Group A was dry
and clean. This construct resulted in the fastest absorption
and was combined solidly with the surrounding wound.
Furthermore, the wound healing rate was significantlyfaster compared with the other groups (Figure 6d,e,f,g,h,i,j,
k,l). Meanwhile, we analyzed rat wound healing rates at 7,
14 and 21 days (Figure 6m); after 14 and 21 days, a statis-
tically significant difference was observed between the ex-
perimental group (Group A) and the other three groups
(Groups B to D, P <0.05). After 21 days, the wound heal-
ing rate in Group A was 1.3-fold, 1.65-fold and 1.96-fold
higher than in Groups B, C and D, respectively.
Hematoxylin and eosin staining of the transplanted
scaffold
After 7 days, small microvessels were generated in the
transplanted scaffold in both Group A and Group B
Figure 5 Transplantation of the cell-seeded scaffold. (a) After anesthesia with 1% (w/v) sodium pentobarbital, disinfection was carried out
with iodine and hair removal treatment was performed in the surgical area. (b), (c) The skin subcutaneous superficial fascia was incised and the
skin substitute transplanted. (d) The specially designed flexible protective coat was used to prevent damage to the affected area from rat bites,
preventing contamination and destruction.
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was loosely structured with uniform cell distribution,
while the trestle structure of Group C was compact
(Figure 7c), with a small number of cells aggregated at
the subcutaneous junctions. After 14 days, Group A
and Group B were observed to have good scaffold in-
fill of cells; however, the scaffolds had different levels
of absorption (Figure 7d,e). Newly generated blood
vessels were significantly increased in Group A. In
comparison, subcutaneous tissue cells continued mi-
grating into the scaffold; however, numbers were lim-
ited in Group C. After 21 days, part of the epidermis
appeared to undergo epidermalization in Group A
(Figure 7g). This was observed within the whole layer,
and a large number of new vessels with homogeneous
distribution were observed. The degree of vascularization
in Group B was not comparable with that of the experi-
mental group (Group A; Figure 7h), and only a few vessels
were seen in Group C (Figure 7i).
Immunohistochemical staining and microvessel density
count
At each time point after surgery, CD31-positive expres-
sion was significantly higher in Group A than in Groups B
and C (Figure 8a,d,g). Furthermore, it was found using
α-SMA that the vascular morphology of Group A was largest
with the highest blood vessel maturation (Figure 9a,d,g).
The number of new blood vessels in Group B was second
highest (Figure 8b,e,h) but with relatively small bloodvessels (Figure 9b,e,h). In the Group C scaffold, CD31
expression was negligible (Figure 8c,f,i) with only a trace
of α-SMA expression (Figure 9c,f,i). Furthermore,
CD31-positive expression was confined within the scaf-
fold and the contacting zone of the subcutaneous tissue.
At the nearside to the subcutaneous tissues, the number
of blood vessels growing into the rat body was more
abundant, but to a lesser extent compared with the ex-
perimental group (Group A). Furthermore, after 21 days
in Groups A and B, different levels of epidermalization
appeared and the cells in the epidermis were highly
aggregated.
Cell counts using Image Pro Plus 6.0 software found
after 7, 14 and 21 days that MVD counts in Group A
were 36.7 ± 11.9, 110.3 ± 11.3 and, 234.7 ± 17.8/mm2,
respectively. These counts were significantly higher
than in Groups B and C. MVD counts in Group B were
11.0 ± 4.7, 39.3 ± 4.9 and 71.3 ± 10.0/mm2, respectively,
while in Group C they were lowest at 7.3 ± 5.8, 18.7 ± 11.4
and 31.3 ± 3.4/mm2. After 21 days, the MVD of Group A
was 3.29-fold and 7.49-fold greater than Group B and
Group C, respectively. At each time point, there was a sta-
tistically significant difference (P <0.05) between Group A
and Groups B and C (Figure 8j).
Immunogenicity results
During the experimental period, there was no skin wound
redness, exudate, infection or other changes observed in
Groups A to C, and all transplanted tissue-engineered skin
Figure 6 Postoperative skin wound. (a) to (l) After 7, 14 and 21 days, there were no visible signs of wound inflammation in all four groups, the
graft was in close contact with the wound, and the wound of Group D was dry and clean with red granulation. (m) Wound healing rates of
Groups A to C were fast after 7 days, with the graft absorption speed in Group A being fastest at 14 and 21 days. In Group A, the graft combined
solidly with its surrounding tissue, and the wound healing rate was significantly higher than in other groups. *P <0.05. Gel-C6S-HA, gelatin–chondroitin-6-
sulfate–hyaluronic acid; HFSC, hair follicle stem cell; VEGF, vascular endothelial growth factor.
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immunofluorescence staining, a minority of cells expressed
a trace of red fluorescence in the three-dimensional skin
transplanted scaffolds (Figure 10). Within the 21 days, al-
most no significant difference was detected in theexpression of MHC-I antibodies in Groups A, B and C.
Based on enlarged images and careful observation, we can
find that there were a little bit of red dots within the first
14 days in Groups A and B (Figure 10a,b,d,e). Expression
of MHC-I was absent from cells in the groups.
Figure 7 Hematoxylin and eosin staining of the graft. (a), (b), (c) After 7 days, skin grafts in Groups A and B had formed microvessels, the
three-dimensional morphology of the scaffold was loosely structured and cell distribution was uniform; conversely, the Group C scaffold was clear.
(d), (e), (f) After 14 days, the newly formed vessels in Group A were significantly increased with relatively fewer in Group B. Scaffolds in Group A
and B were full of uniformly distributed cells, with varying degrees of degradation and absorption. Subcutaneous tissue cells tended to migrate
into the Group C scaffold material, but numbers remained limited. (g), (h), (i) After 21 days, new blood vessels with uniform distribution could be
found within the full layer of Group A, and these vessels were large and abundant. Vascularization in Group B was different from that in Group A,
with only a few blood vessels formed at the junctions between the subcutaneous tissue and scaffold in Group C. Scale bars: 100 μm. Gel-C6S-HA,
gelatin–chondroitin-6-sulfate–hyaluronic acid; HFSC, hair follicle stem cell; VEGF, vascular endothelial growth factor.
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In the past 20 years, research and development on skin
tissue engineering has made great progress, and the ef-
fective use of tissue-engineered skin to treat large skin
defects has become a hot topic of study, now considered
one of the best treatment approaches to repair skin de-
fects [31,32]. However, even with increased research, the
occurrence of clinically applied tissue-engineered skin is
low. One of the main reasons for this is the difficulty in
vascularization of the tissue-engineered skin.
In this study, Gel-C6S-HA scaffolds combined with
VEGF165 gene-modified rHFSCs were used as skinsubstitutes. Cell-seeded scaffolds were transplanted in a
rat model with a full-layer thickness skin defect, to
investigate the role and influence of the construct on
vascularization of tissue-engineered skin at different
time points.
During the continual development of skin tissue engin-
eering approaches, stem cells are a frequently investigated
cell source; however, this is not without limitations. Em-
bryonic stem cells, mesenchymal stem cells, epidermal
stem cells and HFSCs have all been reported as useful
tissue engineering cell sources, and each has its own ad-
vantages and disadvantages. Embryonic stem cells have
Figure 8 (See legend on next page.)
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Figure 8 Markers of new blood vessels. (a), (d), (g) At each time point after surgery, positive expression (brown) of CD31 in Group A was most
abundant. (b), (e), (h) In Group B, CD31 expression was lower than Group A, and the vessels were relatively small. (c), (f), (i) In Group C, CD31
was significantly lower than that in Groups A and B, with only trace expression. (j) Vessel density results. Scale bars: 100 μm. Group A was
compared with Groups B and C, *P <0.05. Gel-C6S-HA, gelatin–chondroitin-6-sulfate–hyaluronic acid; HFSC, hair follicle stem cell; VEGF, vascular
endothelial growth factor.
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and legal problems exist in harvesting and applying this
cell source, which severely limits its therapeutic use
[33,34]. Mesenchymal stem cells are easily isolated and
cultured, have strong proliferative capacity and low im-
munogenicity. Although mesenchymal stem cells can beFigure 9 Markers of mature blood vessels. (a), (d), (g) At each time poi
highest vascular maturity in Group A. (b), (e), (h) Mature vessels were smal
layer of the scaffold in Group C, and the positive expression (brown) zone
more blood vessels growing into the scaffold when it was closer to the su
the experimental group (Group A). Scale bars: 100 μm. Gel-C6S-HA, gelatin–
VEGF, vascular endothelial growth factor.induced to differentiate into epidermal cells and fibro-
blasts, limitations include donor site morbidity and low
harvest volume [35,36]. Epidermal stem cells can form
tissue-engineered skin with hair follicles, sweat glands
and other subsidiary organs, but again problems exist in
using this cell type. Often, the new and large area ofnt after surgery, vessels were larger and uniformly distributed with the
ler in Group B. (c), (f), (i) There were almost no vessels in the upper
was confined to the junction of the subcutaneous tissue. There were
bcutaneous tissue, but the number remained small and fewer than in
chondroitin-6-sulfate–hyaluronic acid; HFSC, hair follicle stem cell;
Figure 10 Major histocompatibility complex class I immunofluorescence staining. Yellow boxes and arrows highlight major
histocompatibility complex class I (MHC-I) antibody expressed on the cytomembrane. Within the 21 days, almost no significant difference was
detected in the expression of MHC-I antibodies in the three groups. (a), (b), (d), (e) There were a few red dots within the first 14 days in Groups
A and B. (c), (f), (i) Postoperative at 21 days, there was no visible MHC-I expression in all cells migrating into the scaffold in Group C. Scale bars:
50 μm. Gel-C6S-HA, gelatin–chondroitin-6-sulfate–hyaluronic acid; HFSC, hair follicle stem cell; VEGF, vascular endothelial growth factor.
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allograft immune rejection reaction [37,38]. HFSCs are
reported to have a strong proliferative capacity and po-
tential to differentiate towards full-thickness layer skin
cells. With such an abundant source of hair follicles and
convenience in obtaining the cells with minimal trauma,
HFSCs appear to be an ideal cell source for tissue-
engineered skin [25-27,39,40]. HFSCs exist predomin-
antly in the hair follicle bulge and have fast and strong
adhesion characteristics [21-23,41]. Using a mixed enzyme
digestion, microdissection and a differential adherence
sorting method (Figure 2a,b,c,d,e,f ), HFSCs with a strong
proliferative capacity were obtained in this study
(Figure 2g,h). Interestingly, when applied for 21 days
in vivo, the transplanted materials in the groups withinoculated rHFSCs had different degrees of epidermali-
zation tendency, while the scaffold without rHFSCs did
not result in epidermalization. We speculate that HFSCs
secrete a variety of cytokines to promote wound healing,
including epidermal growth factor and basic fibroblast
growth factor, to name a few. When implanted in an in-
ternal environment in vivo, these cells probably differenti-
ate into epidermal cells and play a role in promoting early
vascularization of the wound.
Key requirements for tissue-engineered skin include
living cells and a suitable scaffold material for cell
growth interactions. Current skin substitutes do not
have vascular structures or a source of nutrition them-
selves, and blood vessels from the surrounding tissues
are required to grow into them to create a loop, thus
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we used gelatin, chondroitin-6-sulfate and hyaluronic
acid as an extracellular matrix for biomimetic skin
cells. Following cell inoculation into the Gel-C6S-HA
scaffolds, cells were uniformly diffused into the scaffold
pores, and adhered and migrated along the scaffold struc-
ture in a timely manner to grow three-dimensional tissue
(Figure 4a,b,c,d,e,f ). Previous studies on scaffold structure
have shown that during the early period after transplant-
ation, before microcirculation is established between the
tissue-engineered skin and wound, cells in the trans-
planted materials beyond 200 μm usually die in absence of
adequate nutritional support [42]. The three-dimensional
structure of the scaffold could therefore significantly im-
prove the communication rate and water permeability
(Figure 1) to meet requirements, by ensuring high porosity
and high surface area to enhance cell adhesion and migra-
tion, thus promoting vascularization of the new skin
[43-45]. In our study, we found no significant difference in
rHFSC morphology, adhesion and proliferative capacity
on Gel-C6S-HA scaffolds compared with the control
group (Figure 4g).
The formation of newly formed blood vessels within
tissue-engineered skin substitutes is a key factor in evalu-
ating their vascularization capability. CD31, as a trans-
membrane protein, is a good marker of endothelial cells
and can be used to identify newly formed blood vessels
owing to their high sensitivity and specificity [46,47]. α-
SMA is expressed primarily in the vascular middle layer,
specifically identifying smooth muscle cells surrounding
endothelial cells, and can be used to determine the level of
maturity of newborn blood vessels and to identify mature
vessels [48]. By applying immunohistochemical staining
and MVD counting to our in vivo studies, we found that
post-treatment positive expression of both CD31 and α-
SMA reached a maximum in Group A. Group A also had
the greatest number of new blood vessels formed and the
most blood vessel maturation. Smaller blood vessels were
formed in Group B; however, their total was relatively low
with a small size in comparison. The three-dimensional
characteristics of these two skin grafts (Groups A and B)
were loosely structured with uniform cell distribution.
Conversely, the scaffold pore structures in Group C were
compactly structured and a small number of cells aggre-
gated at the subcutaneous junctions and migrated into the
scaffold. Only the subcutaneous tissue had a small amount
of mature blood vessels growing into the scaffold (Figures 8
and 9). In our study, we have shown VEGF165 stable-
expressing HFSCs play an important role, by signifi-
cantly enhancing the amount of VEGF165 protein short
term, to create a high VEGF165 level repair microenvir-
onment. This in turn improves and promotes the early
vascularization process of skin substitutes, thus facilitat-
ing wound healing.Immune rejection is still a key factor to consider when
transplanting tissue-engineered skin. Expression of MHC-
I can be used as an important immune rejection marker
during the early period of tissue-engineered skin trans-
plantation [49,50]. In our study, there were a few red dots
within the first 14 days in Groups A and B (Figure 10a,b,d,e).
We speculate that these tiny particles in the boxes and
arrows in yellow might represent a staining artifact that
was caused by experimental operation. Radically speak-
ing, there is no obvious expression of MHC-I. Following
observation and analysis of the wound after surgery, sig-
nificant swelling, exudate and infection were absent in
all groups (Figure 6); the level of immune rejection was
therefore acceptable and would permit survival of the
transplanted skin substitutes.
Conclusions
After transplantation of VEGF165 gene-modified rHFSCs,
seeded on three-dimensional Gel-C6S-HA constructs,
into full-thickness layer skin defects, the VEGF165 level in
the repair microenvironment was increased. This in turn
significantly improved the partial revascularization ability
of the tissue-engineered skin, thus promoting wound heal-
ing. This tissue-engineered skin strategy has excellent
feasibility and efficacy, providing an important theoretical
basis for further research and development of skin re-
placement constructs, with a view to their future clinical
application.
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